# Cystic Tumors of the Pancreas: A Patient's Guide to Diagnosis, Risk, and Management Pancreatic cystic lesions — fluid-filled sacs in the pancreas — are found in 13% to 18% of healthy people who undergo CT or MRI scans, yet doctors still struggle to tell which ones are harmless and which could turn into cancer. This review explains the types of cysts, how doctors classify them, the strengths and weaknesses of imaging and fluid tests, and what major international guidelines recommend. The authors conclude that current uncertainty causes both unnecessary surgeries and dangerous delays, and they call for more accurate, affordable, and accessible ways to stratify risk for every patient with a pancreatic cyst. # Cystic Tumors of the Pancreas: A Patient's Guide to Diagnosis, Risk, and Management ## Table of Contents - Key Points - Why This Research Matters - Types of Pancreatic Cysts: From Harmless to Premalignant - Diagnostic Tools: How Doctors Evaluate a Cyst - International Guidelines: Three Approaches to Care - Challenges in Clinical Management - Emerging Tools and Future Directions - What This Means for Patients - Study Limitations - Recommendations for Patients - Frequently Asked Questions - Source Information ## Key Points - Pancreatic cysts are found in 13% to 18% of healthy people undergoing CT or MRI; most are benign or slow-growing, but some carry malignant potential. - Cyst type matters more than size alone: pseudocysts and serous cystadenomas are usually harmless, while MCNs and main duct IPMNs carry higher cancer risk. - Cyst fluid CEA is less specific than once thought; a large retrospective study of 1,169 cases found an optimal cutoff of 20 ng/mL, not the traditional 192 ng/mL. - In a 2025 study by Wang and colleagues, EUS rarely changed diagnosis in low-risk cysts but influenced management in about 30% of cases overall. - The Fukuoka, AGA, and European guidelines disagree on surveillance and surgery thresholds, creating real-world variation in care and a need for more unified approaches. ## Why This Research Matters Pancreatic cystic lesions (PCLs) — better known as pancreatic cysts — are becoming a very common finding in modern medicine. The main reason is the widespread use of cross-sectional imaging such as computed tomography (CT) scans and magnetic resonance imaging (MRI). Studies estimate that between 13% and 18% of people without any symptoms have one of these cysts, especially older adults. Most pancreatic cysts are benign or slow-growing. Others carry significant malignant potential. In fact, cystic lesions account for about 15% of pancreatic ductal adenocarcinoma cases — the most common and deadly form of pancreatic cancer. Pancreatic cysts cover a broad spectrum. They range from benign pseudocysts to premalignant and malignant tumors such as intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs). "Premalignant" means the lesion has the potential to become cancer but has not done so yet. Accurate diagnosis matters for two opposite reasons. On one hand, overtreatment can lead to unnecessary pancreatic surgery, which carries major risks. On the other hand, undertreatment can delay the diagnosis of a potentially curable pancreatic cancer. Despite many available tools, risk stratification (deciding which cyst is dangerous) remains imperfect. The rate of surgery for non-malignant cysts is still high. Current guidelines from different societies do not always agree. This inconsistency creates confusion in everyday practice. Meanwhile, the psychological and economic burden of long-term surveillance is growing for patients and healthcare systems alike. This minireview aims to give a comprehensive, up-to-date overview of pancreatic cyst classification, diagnosis, and management. It also explores emerging technologies and makes the case for more precise, accessible, and cost-effective risk-stratification pathways. ## Types of Pancreatic Cysts: From Harmless to Premalignant Correct classification is the foundation of all clinical decisions. Each cyst type behaves differently, so doctors need to know exactly what they are dealing with. Here is an overview of the main categories, based on cause and malignant potential. ### Non-neoplastic cystic lesions **Pseudocysts** are the most common cystic lesions of the pancreas. They form when fluid rich in pancreatic enzymes becomes encapsulated (walled off) after acute pancreatitis, chronic pancreatitis, trauma, or a break in the pancreatic duct. Unlike true cysts, pseudocysts have no epithelial lining — they are surrounded only by fibrous tissue. A history of pancreatitis or injury is often the key clue for diagnosis. Most pseudocysts resolve on their own or with supportive and endoscopic therapy. Surgery is rarely needed unless complications develop. ### Benign neoplastic lesions **Serous cystadenomas (SCAs)** are benign tumors made of many small cysts lined by glycogen-rich cuboidal epithelial cells, supported by a fibrous stroma (framework tissue). They account for roughly 30% of all pancreatic cystic neoplasms — about 1 in 3. SCAs appear most often in older women and usually sit in the head of the pancreas. These tumors do not connect with the pancreatic duct and rarely turn malignant. Most cause no symptoms and need no treatment unless they grow large enough to push on nearby organs (called mass effect). SCAs can also be seen in people with von Hippel-Lindau disease, an inherited condition that promotes cyst and tumor formation. ### Premalignant and malignant cystic neoplasms **Mucinous cystic neoplasms (MCNs)** are mucus-producing tumors that almost exclusively affect middle-aged women. They usually develop in the body or tail of the pancreas. The defining feature is ovarian-type stroma (tissue resembling the ovary) seen under the microscope, and they do not communicate with the pancreatic duct. Many MCNs are benign, but up to one-third may already harbor high-grade dysplasia or invasive carcinoma (early cancer). Published risk estimates for high-grade dysplasia or invasive cancer within an MCN range from 10% to 39%. Because of this malignant potential, **all MCNs are considered surgical lesions**, meaning doctors generally recommend removing them. **Intraductal papillary mucinous neoplasms (IPMNs)** are tumors in which mucus-producing cells grow abnormally inside the pancreatic ducts. There are two main types: - **Main duct type** — arises in the main pancreatic duct; carries a malignancy risk of approximately 38% to 68% - **Branch duct type** — arises in smaller branches; considered the most common pancreatic cyst; carries a malignancy risk of approximately 22% IPMNs are more common in older men and can appear in multiple spots (multifocal disease). They are regarded as precursor lesions to pancreatic adenocarcinoma. Management must be individualized, taking into account both risk features and the patient's overall health. **Solid pseudopapillary neoplasms** are rare, low-grade malignant tumors that mainly affect young women, especially those of Asian or African descent. They are made of loosely cohesive epithelial cells arranged in pseudopapillary patterns. Although these tumors grow slowly, they can become large and press on surrounding tissue. Surgical resection cures most cases, and recurrence is rare. ### Rare and miscellaneous cystic lesions **True epithelial cysts** (congenital cysts) are rare and usually cause no symptoms. They are lined with cuboidal epithelium and have no neoplastic potential. Most are found incidentally and can be associated with systemic syndromes such as von Hippel-Lindau disease. **Ductal adenocarcinoma with cystic degeneration** occurs when the typically solid pancreatic cancer develops areas of fluid due to central necrosis (tissue death) or blocked branch ducts. These lesions can mimic benign cysts, but they usually show signs of invasive cancer such as duct obstruction, vascular encasement (tumor wrapping around blood vessels), or rapid growth. Cystic-looking adenocarcinoma should always be suspected in the right clinical context. **Other rare entities** that can appear as cysts include lymphangiomas, cystic teratomas, sarcomas, paragangliomas, and metastatic lesions (for example, from renal cell carcinoma). These are exceedingly rare and are usually diagnosed by histology (tissue analysis) or genetic testing after surgical removal. **Cystic neuroendocrine tumors (cNETs)** are uncommon pancreatic cysts that may be associated with multiple endocrine neoplasia type 1 (MEN1), an inherited cancer syndrome. They account for only a small percentage of pancreatic cysts. Some are found by chance; others cause abdominal pain or weight loss. On CT and MRI, cNETs typically appear as well-defined masses, sometimes with calcium deposits. Endoscopic ultrasound (EUS) can detect cysts with solid components, which raises suspicion for a cNET. Management depends on hormone activity: functional cNETs, such as insulinomas (tumors that secrete too much insulin), usually require surgery. Non-functional cNETs are typically removed if they exceed 3 cm or show signs of malignancy. Patients with MEN1 need close monitoring because of their higher risk for multifocal tumors and cancer. ## Diagnostic Tools: How Doctors Evaluate a Cyst Each diagnostic tool has different strengths in accuracy, accessibility, and cost. No single test is perfect, so a multimodal approach — combining imaging, endoscopic techniques, cyst fluid analysis, and sometimes molecular diagnostics — is usually necessary. ### Cross-sectional imaging **MRI with cholangiopancreatography** is the preferred noninvasive test for the initial evaluation of pancreatic cysts. It gives high-resolution views of cyst shape, whether the cyst connects to the pancreatic ducts, internal septations (wall divisions), and mural nodules (small solid growths on the cyst wall). MRI also uses no ionizing radiation, which makes it well suited for long-term surveillance. **CT** is widely available and offers excellent spatial resolution. It is especially helpful for spotting calcifications, mural nodules, and cyst wall thickening — features that may indicate malignant potential. However, CT is less sensitive than MRI for subtle findings such as communication with the pancreatic duct. ### Endoscopic ultrasound (EUS) EUS plays a central and evolving role in diagnosis, especially for cysts with intermediate (borderline) risk. The doctor passes a thin, flexible tube with an ultrasound probe through the mouth into the stomach and duodenum, right next to the pancreas. This gives high-resolution images of cyst structure and blood vessels, and it is particularly good at finding mural nodules, septations, and blood vessel invasion. Because only a small fraction of pancreatic cysts progress to cancer, EUS has become a critical tool for preventing unnecessary surgery and tailoring surveillance. EUS-guided fine-needle aspiration (FNA) allows doctors to sample cyst fluid for biomarkers such as carcinoembryonic antigen (CEA, a protein often elevated in mucinous cysts), glucose, and amylase (an enzyme that suggests duct communication). The same sample can be sent for cytology and DNA mutation testing such as KRAS and GNAS. Advanced EUS techniques add even more information: - **Contrast-enhanced harmonic EUS (CH-EUS)** distinguishes true mural nodules from mucus or debris. In a study by Harima, CH-EUS showed significantly superior accuracy for detecting mural nodules — 98% — compared to CT at 92% and conventional EUS at 72%. The differences were statistically significant (CT vs CH-EUS, P < 0.05; conventional EUS vs CH-EUS, P < 0.01). - **EUS elastography**, which measures tissue stiffness, is still under investigation but may help tell benign from malignant lesions. A 2025 study by Wang and colleagues found that EUS rarely changes the diagnosis in low-risk cysts. However, it influences management in about 30% of cases by refining surgical decisions and surveillance plans. Agreement between cross-sectional imaging and EUS was high — 97% for high-risk stigmata (very concerning features) and 94% for worrisome features. Still, EUS often reclassified lesions, particularly those near key decision thresholds such as mural nodules smaller than 5 mm or cysts close to 3 cm in size. The takeaway: these findings support a more selective use of EUS. It is most valuable for indeterminate or intermediate-risk lesions, where it can confirm or rule out malignant potential. ### Cyst fluid analysis Biochemical analysis of cyst fluid plays a supporting role in diagnosis, but no single marker is definitive. **Cyst fluid CEA** remains one of the most widely used markers for distinguishing mucinous from non-mucinous cysts. The traditional cutoff was 200 ng/mL or more, commonly cited as ≥ 192 ng/mL, to suggest a mucinous (mucus-producing) origin. However, new data challenge this number. A large retrospective study of 1,169 cases — including 394 histologically confirmed lesions and 237 with confirmatory molecular profiles (such as KRAS, GNAS, or RNF43 mutations) — found the following: - Median CEA levels were significantly higher in mucinous cysts: 323.9 ng/mL vs 204.6 ng/mL in non-mucinous cysts (P < 0.001, meaning less than a 0.1% chance this finding was random). - The optimal cutoff for distinguishing cyst type was much lower than traditionally used — just 20 ng/mL — which gave high sensitivity of 89% but modest specificity of 64%. - At the conventional threshold of 192 ng/mL, sensitivity fell to 56%, while specificity rose to 78%. - To reach the 85% specificity reported in older studies, a higher threshold of 250 ng/mL was needed — but this caused more false negatives. In plain terms, CEA is still valuable, but it is less specific than previously believed. Results must be interpreted together with imaging, clinical features, and cytology or molecular testing. **Amylase** levels in cyst fluid are elevated when the cyst communicates with the pancreatic duct, as in pseudocysts and IPMNs. However, amylase does not help distinguish mucinous from non-mucinous tumors. **Glucose** has gained attention recently. Low cyst fluid glucose (below 50 mg/dL) is a low-cost, accessible, and relatively sensitive marker for mucinous cysts. Several studies suggest glucose may even outperform CEA in specific settings, partly because the result is easy to interpret and the test is widely available. Still, no biomarker — alone or in combination — provides absolute diagnostic certainty. ### Cytology Cyst fluid cytology is highly specific when positive. In other words, if the laboratory finds malignant cells, the diagnosis is almost certainly correct. The problem is poor sensitivity: most cysts contain very few cells, so the test often misses disease that is present. A positive cytology result for high-grade dysplasia or malignancy is rare but clinically decisive when it occurs. ### Molecular diagnostics Molecular analysis of cyst fluid is a significant advance, particularly for telling cyst subtypes apart and predicting malignant potential. Specific gene changes are linked to specific lesions: - **KRAS and GNAS mutations** are commonly found in IPMNs. - **RNF43, TP53, and PIK3CA mutations** are more often associated with high-grade dysplasia or invasive carcinoma. Despite this promise, molecular diagnostics are rarely used in routine practice. The barriers are real: high costs, limited availability outside specialized centers, and a lack of standardization in which genes are tested, which platforms are used, and how results are interpreted. Studies also vary in the sensitivity and specificity of molecular findings, which complicates real-world use. Emerging techniques may change this. **Next-generation sequencing (NGS)** provides a comprehensive profile of many genetic changes at once, helping classify the cyst. **Digital droplet polymerase chain reaction (ddPCR)** is highly sensitive at detecting specific mutations, even when the cyst fluid sample is very small. The clinical stakes are high. Identifying high-risk mutations such as KRAS or TP53 can help guide whether surgery is necessary. But until costs fall and standardization improves, molecular testing will remain a specialized tool rather than a routine one. ## International Guidelines: Three Approaches to Care Several professional societies have issued guidelines for evaluating and managing pancreatic cysts. The three most widely used frameworks are the Fukuoka guidelines (2017), the American Gastroenterological Association (AGA) guidelines (2015), and the European evidence-based guidelines (2018). They differ in important ways, which leads to variation in care between institutions and specialists. ### Fukuoka guidelines The Fukuoka guidelines focus mainly on IPMNs and MCNs. They stratify patients using specific clinical and radiological features: 1. **High-risk stigmata** — obstructive jaundice (yellowing caused by blockage), an enhancing mural nodule ≥ 5 mm, or a main pancreatic duct diameter ≥ 10 mm. These features warrant immediate surgical referral. 1. **Worrisome features** — cyst size ≥ 3 cm, mural nodules smaller than 5 mm, thickened or enhancing cyst walls, main duct dilation of 5–9 mm, or a history of pancreatitis. These warrant further evaluation with EUS. 1. **Surveillance** — recommendations are individualized based on cyst features. Fukuoka suggests lifelong monitoring for patients with IPMNs because of their potential for malignant transformation. ### AGA guidelines The AGA guidelines take a more conservative, cost-conscious approach. Their goal is to reduce unnecessary surgeries. Key points include: - Surveillance is recommended only for patients with **two or more high-risk features**, such as cyst size ≥ 3 cm, a solid component, or main pancreatic duct dilation. - Surgical referral is advised if additional concerning features appear on imaging or EUS-FNA, including positive cytology or elevated cyst fluid CEA. - If a cyst remains stable with no worrisome features for five years, the AGA recommends **stopping surveillance**. This strategy minimizes overtreatment. However, critics point out that it has lower sensitivity for detecting high-grade dysplasia or early malignancy compared with more aggressive guidelines such as Fukuoka. ### European guidelines The European evidence-based guidelines (2018) cast a wider net by addressing all types of pancreatic cystic lesions, mucinous and non-mucinous alike. Their key recommendations: 1. Risk stratification should combine imaging characteristics with cyst fluid biomarkers. 1. Cases with indeterminate or borderline features should be discussed by a multidisciplinary team (multiple specialists reviewing together). 1. Surveillance protocols should be tailored to cyst type, size, patient age, and comorbidities, enabling more individualized care. 1. MRI should be preferred over CT for routine follow-up because of its superior soft-tissue contrast and lack of radiation. EUS-FNA and molecular analysis should be applied selectively to clarify unclear lesions. These three frameworks reflect different clinical philosophies, ranging from aggressive surgical intervention to risk-adapted, conservative surveillance. The review authors emphasize the need for more unified, evidence-based approaches that balance diagnostic accuracy, patient safety, and healthcare resources. ## Challenges in Clinical Management All guidelines aim to balance risk against cost and patient burden. Yet their differing thresholds for intervention and surveillance create inconsistencies and real-world uncertainty. Without unified criteria, clinicians lack standardized pathways that integrate clinical features and new diagnostic technologies. ### Overdiagnosis and overtreatment High-resolution imaging is now used so widely that doctors detect many more pancreatic cysts — most of them indolent (slow-growing and harmless) or benign. The problem is that some patients then undergo unnecessary pancreatic surgery for benign lesions. Pancreatic resection is a major operation with significant procedural risks, long recovery times, and lasting effects on digestion and blood sugar control. The review notes that this overtreatment exposes patients to harm without benefit. Many of these surgeries could be avoided with better risk stratification. ### Undertreatment and delayed intervention The opposite danger is just as real. Diagnostic uncertainty can delay intervention for high-risk cysts. When a dangerous cyst is misclassified as low-risk, patients may miss the window for cancer prevention. Because some cysts are true precursor lesions to pancreatic adenocarcinoma, timely surgery can be lifesaving. ### The burden of surveillance Prolonged — and often unnecessary — surveillance takes a toll. Patients face repeated imaging tests, endoscopic procedures, and doctor visits. The psychological burden of living with a "possibly precancerous" finding causes anxiety. The financial burden affects both patients and healthcare systems. The authors call this a significant and growing problem that demands more precise diagnostic and management strategies. ## Emerging Tools and Future Directions The review highlights several emerging technologies that may improve pancreatic cyst management: - **Radiomics** — using computers to extract hundreds of detailed features from standard medical images that the human eye cannot see, potentially improving malignancy prediction. - **Artificial intelligence (AI)** — machine learning models that may eventually help classify cysts and predict outcomes more accurately than current criteria. - **Next-generation sequencing (NGS)** — comprehensive genetic profiling of cyst fluid to identify mutations and guide personalized decisions. - **Novel biomarkers** — new molecular and biochemical markers beyond CEA, glucose, and amylase that could improve diagnostic precision. - **Pancreatoscopy** — direct visualization of the inside of the pancreatic duct, allowing doctors to see lesions and take targeted samples. The authors stress an urgent need for diagnostic pathways that are cost-effective, accurate, and accessible to all patients — not just those treated at large specialized centers. A more refined risk stratification approach, they argue, is essential to optimize outcomes, reduce healthcare waste, and improve quality of life. ## What This Means for Patients If you have been diagnosed with a pancreatic cyst, this review holds several practical messages. First, a cyst diagnosis is not a cancer diagnosis. The majority of pancreatic cysts are benign or slow-growing. Even among mucinous types, only a fraction progress to cancer, and the risk varies widely by type — from about 22% for branch duct IPMNs to 38%–68% for main duct IPMNs. Second, tests have real limitations. Imaging can miss subtle signs. CEA levels are less definitive than once thought: at the traditional cutoff of 192 ng/mL, the test catches only 56% of mucinous cysts (sensitivity) while correctly identifying 78% of non-mucinous cysts (specificity). Lowering the cutoff to 20 ng/mL catches more (89%) but produces more false alarms (64% specificity). This is why doctors rarely rely on a single test. Third, surveillance may be recommended for years — sometimes lifelong. This is uncomfortable, but it reflects the reality that some cysts can change over time. Fukuoka guidelines support lifelong monitoring for IPMNs. AGA guidelines, by contrast, suggest stopping after five stable years. If your doctor recommends long-term follow-up, ask which guideline they follow and why. Fourth, EUS is not needed for every cyst. The 2025 study by Wang and colleagues showed that EUS rarely changes the diagnosis in low-risk cysts but influences management in about 30% of cases overall — mainly by clarifying surgical decisions and surveillance plans. If your cyst has intermediate-risk features, EUS may be the single most useful next step. ## Study Limitations This article is a minireview, meaning it summarizes existing research rather than presenting new patient data. Several limitations should be acknowledged: - The natural history of many pancreatic cystic lesions remains incompletely understood, despite multiple classification and management strategies. - Diagnostic tools are constrained by either suboptimal sensitivity or high costs, and no single marker offers definitive accuracy. - Molecular diagnostics are promising but limited in routine practice by cost, access, and lack of standardization. - The three major guidelines disagree in clinically significant ways, and the evidence base for some recommendations — such as when to stop surveillance — remains thin. ## Recommendations for Patients Based on this review, here is practical advice for patients living with a pancreatic cyst: 1. **Know your cyst type.** Ask your doctor whether you have a pseudocyst, serous cystadenoma, MCN, IPMN, or another type. Type determines risk more than size alone. 1. **Understand your risk category.** Ask whether your cyst has high-risk stigmata (jaundice, enhancing nodule ≥ 5 mm, main duct ≥ 10 mm) or worrisome features (size ≥ 3 cm, nodules < 5 mm, thickened walls, duct dilation of 5–9 mm, or pancreatitis history). These terms guide whether surgery or EUS is recommended. 1. **Ask about a multidisciplinary review.** The European guidelines strongly recommend that indeterminate cases be discussed by a team of gastroenterologists, radiologists, surgeons, and pathologists. If your case is borderline, a second opinion at a specialized pancreatic center can be valuable. 1. **Follow your surveillance schedule.** If imaging is recommended every 6 or 12 months, keep those appointments. MRI is generally preferred over CT to avoid radiation exposure. 1. **Do not fear EUS.** It is the best tool for clarifying intermediate-risk cysts, and it can detect mural nodules with up to 98% accuracy when contrast enhancement is used. 1. **Ask about molecular testing.** If your cyst fluid is being analyzed, ask whether KRAS, GNAS, RNF43, TP53, or PIK3CA testing is available and whether it would change your management plan. Be aware that these tests are not yet standard everywhere. 1. **Weigh surgery carefully.** All MCNs are generally considered surgical because of a 10%–39% risk of high-grade dysplasia or cancer. Main duct IPMNs carry a 38%–68% malignancy risk and usually require resection. But for low-risk cysts, surgery may cause more harm than the cyst itself. ## Frequently Asked Questions ### I was just told I have a pancreatic cyst. Does that mean I have cancer? No. Most pancreatic cysts are benign or slow-growing. Even among mucinous types, only a fraction progress to cancer, and risk varies widely by type — from about 22% for branch duct IPMNs to 38%–68% for main duct IPMNs. A cyst diagnosis is not a cancer diagnosis. ### What is the difference between a pseudocyst and a serous cystadenoma? Pseudocysts form after pancreatitis, trauma, or a duct break and have no epithelial lining; most resolve on their own or with supportive or endoscopic therapy, and surgery is rarely needed. Serous cystadenomas are benign tumors of small cysts, account for roughly 30% of pancreatic cystic neoplasms, appear most often in older women, and rarely turn malignant. ### What does it mean if my cyst is called an IPMN? IPMNs are mucus-producing tumors growing inside the pancreatic ducts. Main duct type carries a malignancy risk of about 38% to 68%; branch duct type, the most common pancreatic cyst, carries about 22%. They are more common in older men and can appear in multiple spots. Management is individualized based on risk features and overall health. ### Why do doctors recommend removing all mucinous cystic neoplasms (MCNs)? MCNs are mucus-producing tumors that almost exclusively affect middle-aged women, usually in the body or tail of the pancreas. Published risk estimates for high-grade dysplasia or invasive cancer within an MCN range from 10% to 39%. Because of this malignant potential, all MCNs are considered surgical lesions and doctors generally recommend removing them. ### What is cyst fluid CEA and what does my number mean? CEA is a protein often elevated in mucinous cysts. At the traditional cutoff of 192 ng/mL, sensitivity is 56% and specificity 78%. A large retrospective study of 1,169 cases found the optimal cutoff was just 20 ng/mL, giving 89% sensitivity but 64% specificity. CEA is less specific than once believed and must be interpreted with imaging and other tests. ### Do I need an endoscopic ultrasound (EUS) for my cyst? Not necessarily. A 2025 study by Wang and colleagues found EUS rarely changes the diagnosis in low-risk cysts but influences management in about 30% of cases overall, mainly by refining surgical decisions and surveillance plans. EUS is most valuable for indeterminate or intermediate-risk lesions, where it can confirm or rule out malignant potential. ### How long will I need surveillance, and can it ever stop? It depends on which guideline your doctor follows. Fukuoka guidelines support lifelong monitoring for IPMNs because of their potential for malignant transformation. AGA guidelines suggest stopping surveillance if a cyst remains stable with no worrisome features for five years. Ask your doctor which guideline they follow and why. ### When should a patient with a pancreatic cyst seek a second opinion? A second opinion is valuable when a cyst is indeterminate or borderline, since the three major guidelines disagree on when to operate and when to keep watching. Ask whether your cyst has high-risk stigmata or worrisome features, and which guideline your doctor follows. If surgery is proposed for a low-risk cyst, or if a possibly dangerous cyst is being watched, an independent review can help. European guidelines recommend multidisciplinary discussion for indeterminate cases. Diagnostic Detectives Network provides independent expert second opinions. ## Source Information This patient-friendly article is based on peer-reviewed research. - **Original title:** Cystic tumors of the pancreas: Current perspectives on diagnosis and management - **Authors:** Shumka N, Karagyozov PI. --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/cystic-tumors-of-the-pancreas-a-patients-guide-to-diagnosis-risk-and-management